ICU Medical CFO sells 9,307 shares in plan

ICU MEDICAL INC/DE (ICUI) reported that Chief Financial Officer Brian Michael Bonnell sold a total of 9,307 shares of common stock on August 31, 2026 in four open-market transactions.

Rhea-AI Filing Summary

ICU MEDICAL INC/DE (ICUI) reported that Chief Financial Officer Brian Michael Bonnell sold a total of 9,307 shares of common stock on August 31, 2026 in four open-market transactions. The sales, related to a restricted award, were effected under a Rule 10b5-1 trading plan adopted on June 1, 2026, at weighted average prices ranging from about $170.57 to $174.08 per share, each executed over multiple trades within the stated price ranges.

Insider Trade Summary 10b5-1

Net Seller: 9,307 shares

Net Sell 4 txns

Insider Bonnell Brian Michael

Role Chief Financial Officer

Sold 9,307 shs ($1.61M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	1,712	$171.0532	$293K
Sale	Common Stock F1, F3	1,914	$172.1226	$329K
Sale	Common Stock F1, F4	4,568	$173.4437	$792K
Sale	Common Stock F1, F5	1,113	$173.9144	$194K

Holdings After Transaction: Common Stock — 62,443 shares (Direct)

Footnotes (5)

1. F1. The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2026.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.57 to $171.495, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.625 to $172.6, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
4. F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.69 to $173.765, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
5. F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $173.77 to $174.08, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

Key Figures

Shares sold (block 1): 1,712 shares at $171.0532 per share Shares sold (block 2): 1,914 shares at $172.1226 per share Shares sold (block 3): 4,568 shares at $173.4437 per share +5 more

8 metrics

Shares sold (block 1) 1,712 shares at $171.0532 per share Common Stock sale on August 31, 2026

Shares sold (block 2) 1,914 shares at $172.1226 per share Common Stock sale on August 31, 2026

Shares sold (block 3) 4,568 shares at $173.4437 per share Common Stock sale on August 31, 2026

Shares sold (block 4) 1,113 shares at $173.9144 per share Common Stock sale on August 31, 2026

Total shares sold 9,307 shares Aggregate non-derivative Common Stock sales reported in Form 4

Price ranges $170.57 to $174.08 per share Ranges of individual trade prices across the four sale blocks

Rule 10b5-1 plan adoption date June 1, 2026 Date the CFO adopted the Rule 10b5-1 trading plan governing these sales

Number of sale transactions 4 transactions Non-derivative Common Stock sales on August 31, 2026

Key Terms

Rule 10b5-1 trading plan, weighted average price, Form 4, restricted award

4 terms

Rule 10b5-1 trading plan regulatory

"The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Form 4 regulatory

"The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

restricted award financial

"The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ICUI CFO Brian Michael Bonnell report in this Form 4 for ICUI?

He reported four open-market sales of ICU MEDICAL INC/DE (ICUI) common stock on August 31, 2026, totaling 9,307 shares, related to a restricted award and executed under a Rule 10b5-1 trading plan adopted on June 1, 2026.

How many ICUI shares did the CFO sell and on what date?

Brian Michael Bonnell sold a total of 9,307 shares of ICU MEDICAL INC/DE (ICUI) common stock on August 31, 2026, reported across four separate non-derivative transactions in this Form 4 filing.

At what prices were the ICUI shares sold in this Form 4?

The reported weighted average sale prices were $171.0532, $172.1226, $173.4437, and $173.9144 per ICUI share, with individual trades occurring within price ranges from $170.57 up to $174.08 per share.

Was the ICUI CFO’s stock sale made under a Rule 10b5-1 plan?

Yes. The filing states the restricted award sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Brian Michael Bonnell on June 1, 2026, and the Form 4’s Rule 10b5-1 checkbox is marked as affirmed.

Were any derivative securities involved in this ICUI Form 4?

No. All reported transactions involve Common Stock as non-derivative securities, and the derivative summary shows no derivative transactions or remaining derivative positions in this Form 4.

How many ICUI share-sale transactions did the CFO report and what type were they?

He reported four transactions, each coded S for Sale in open market or private transaction. All involve non-derivative ICUI common stock held with direct ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/31/2026 - 04:44 PM EDT Accepted by SEC EDGAR 08/31/2026 - 04:43 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bonnell Brian Michael

(Last) (First) (Middle)

951 CALLE AMANECER

(Street)

SAN CLEMENTE CALIFORNIA 92673

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ICU MEDICAL INC/DE [ ICUI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/31/2026		S		1,712(1)	D	$171.0532(2)	70,038	D
Common Stock	08/31/2026		S		1,914(1)	D	$172.1226(3)	68,124	D
Common Stock	08/31/2026		S		4,568(1)	D	$173.4437(4)	63,556	D
Common Stock	08/31/2026		S		1,113(1)	D	$173.9144(5)	62,443	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted award sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.57 to $171.495, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.625 to $172.6, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.69 to $173.765, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $173.77 to $174.08, inclusive. The reporting person undertakes to provide ICU Medical, Inc., any security holder of ICU Medical, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.

	By: Paula Darbyshire, Attorney-in-Fact For: Brian Bonnell	08/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)